Press Releases

BioIVT Acquires PPA Research Group, Increasing its Ability to Support Drug Development, Cell and Gene Therapy Research

By Lauren Vagnone | October 16, 2019

Acquisition increases BioIVT’s access to normal and disease-state leukopaks, plasma and sera, and expands its cell processing capabilities

BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it has acquired PPA Research Group, Inc., a human hematologic product provider, based in Gray, TN. This acquisition will significantly expand BioIVT’s immunology and disease-state product portfolios, enhancing its ability to support immuno-oncology and cell therapy researchers.
Read more

BioIVT Appoints Global Business Strategist Lori Ball as Its Chief Operating Officer

By Lauren Vagnone | October 2, 2019

Ms. Ball has held senior global leadership roles in the life sciences industry for more than 18 years

BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it has appointed Lori Ball as its chief operating officer (COO). In her new position, Ms. Ball will be responsible for providing leadership and strategic direction on operational and business decisions, including growth planning, business and organizational development, risk management, and quality control.
Read more

BioIVT Joins Medicines Discovery Catapult’s Discovery Services Platform to Support Drug Discovery in the UK

By Lauren Vagnone | September 24, 2019

BioIVT will help to generate drug discovery target validation data and characterize novel therapeutics

BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it has joined UK Medicines Discovery Catapult’s Discovery Services Platform, partnering with other best-in-class service providers to help improve preclinical drug discovery success rates.  
Read more

New BioIVT Research Examines Potential Link Between HIV Integrase Inhibitor Drugs and Neural Tube Defects During Pregnancy

By Lauren Vagnone | August 15, 2019

This research, which investigates the risk of drug-induced folate deficiency with HIV integrase inhibitors, was published in Drug Metabolism and Disposition (DMD)

BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that researchers in its Transporter Sciences Group have co-authored a peer-reviewed DMD paper, which investigates the inhibitory effects of a class of HIV drugs known as integrase inhibitors on folate transporter pathways.
Read more

BioIVT to Host Symposium Highlighting Industry Progress in Immuno-oncology Drug Discovery Research

By Lauren Vagnone | August 7, 2019

Symposium presenters were drawn from pharma, biotech and academia to demonstrate the latest technological innovations in immuno-oncology research

BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it will be hosting a research symposium entitled “Innovation in Immuno-oncology: Breaking Down the Barriers” on Aug. 14. This event, which will highlight research advances with implications for immuno-oncology drug discovery and clinical practice, will be held at the Dante Alighieri Society of Massachusetts in Cambridge, MA.
Read more

BioIVT Acquires Keystone Biologicals, Expands its Offering of Disease-state Biospecimens

By Lauren Vagnone | August 6, 2019

This transaction increases BioIVT’s portfolio of disease-state plasma, sera and controls, and enhances its ability to support the in vitro diagnostic market

BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it has acquired Keystone Biologicals, Inc., a supplier of disease-state plasma, sera and controls, located in Hatboro, PA. This acquisition will expand BioIVT’s disease-state portfolio both by volume and product range.
Read more

BioIVT to Highlight Research Advances Made Using its Hepatocyte Products and Services at the 12th International ISSX Meeting

By Lauren Vagnone | July 23, 2019

BioIVT, a leading provider of research models and services for drug and diagnostic development, today outlined several scientific contributions that it will be making at the 12th International ISSX Meeting.

BioIVT, a leading provider of research models and services for drug and diagnostic development, today outlined several scientific contributions that it will be making at the 12th International ISSX Meeting. This conference will be held from July 28-31 at the Oregon Convention Center in Portland, OR.
Read more

BioIVT to Host Webinar on How to Evaluate BSEP Inhibition and Reduce Drug-induced Liver Injury (DILI) Risk during Drug Development

By Lauren Vagnone | July 10, 2019

DILI is a leading cause of drug development failures and a frequent cause of drug label restrictions

BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it is hosting a webinar that will present the latest in vitro research methods and International Transporter Consortium (ITC) guidance for assessing bile salt export pump (BSEP) inhibition to reduce and manage the risk of drug-induced liver injury (DILI) during drug development.
Read more

BioIVT HEPATOPAC® Meeting to Highlight Advances in Drug Discovery Research

By Lauren Vagnone | June 3, 2019

HEPATOPAC micropatterned hepatocyte cultures are optimized for drug safety, metabolism and efficacy research

BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it will be hosting a HEPATOPAC Meeting at the AC Hotel by Marriott, San Francisco Airport/Oyster Point Waterfront on June 7. Presentations will show how the HEPATOPAC system can be employed in lead selection programs to investigate new drug candidates’ ADME-Tox profiles and assess their efficacy.
Read more

BioIVT Named Service Provider for Promega Immunotherapy Bioassays

By Lauren Vagnone | May 29, 2019

Demonstrating continuing support for immuno-oncology researchers, BioIVT extends excellence in research to help researchers screen novel therapeutics

BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it will now offer Promega Immune Checkpoint and antibody-dependent cell-mediated cytotoxicity (ADCC) Reporter Bioassays to support immunology and immuno-oncology research. This offering complements BioIVT’s custom assay development services using client-provided cells and reagents.Read more